Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Salvador Bofill

Showing results (1-10 of 2) with videos related to

Pageof 1
Sort By:
Plos One|October 21, 2014
The Long-HER study: clinical and molecular analysis of patients with HER2+ advanced breast cancer who become long-term survivors with trastuzumab-based therapyAngelo Gámez-Pozo, Ramón M Pérez Carrión, Luis Manso, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 21, 2023
Patritumab deruxtecan in untreated hormone receptor-positive/HER2-negative early breast cancer: final results from part A of the window-of-opportunity SOLTI TOT-HER3 pre-operative studyM Oliveira, C Falato, J M Cejalvo, et al.
Pageof 1

Showing results (1-10 of 2) with videos related to

Sort By:
Pageof 1
Plos One|October 21, 2014
The Long-HER study: clinical and molecular analysis of patients with HER2+ advanced breast cancer who become long-term survivors with trastuzumab-based therapyAngelo Gámez-Pozo, Ramón M Pérez Carrión, Luis Manso, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 21, 2023
Patritumab deruxtecan in untreated hormone receptor-positive/HER2-negative early breast cancer: final results from part A of the window-of-opportunity SOLTI TOT-HER3 pre-operative studyM Oliveira, C Falato, J M Cejalvo, et al.
Pageof 1